Quercetin supplement tested to boost blood vessel health in obesity
NCT ID NCT06683534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether quercetin, a dietary supplement found in many fruits and vegetables, can improve the function of tiny blood vessels in young adults with obesity. Forty participants will take either quercetin or a placebo daily for 30 days. Researchers will measure blood vessel dilation and density using a camera under the tongue and laser probes on the forearm.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- quercetin (dietary supplement)
- What this could lead to
- If it works, this could point toward a simple supplement to protect blood vessels in people with obesity.
- What could go wrong
- This is a small, early-phase trial with only 40 participants. The supplement may not improve blood vessel function, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Obesity (BMI\>30) * Aged 18-40 years * English Speaking Exclusion Criteria: * BMI\>60 * Resting SBP ≥180 mmHg or DBP ≥ 110mmHg * Pregnancy or breastfeeding. * Prior history of myocardial infarction * Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension) * Active mouth sores that affect the buccal mucosa.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Froedtert Hospital
Wauwatosa, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could monthly texts and automatic risk scores stop heart attacks before they start?
- Can a nurse and a neighbor help tame chronic disease?
- Two eggs a day put to the test for heart health
- A soft patch that watches your heart beat in real time
- Could a quieter, automated blood pressure check help more people control hypertension?
- Can a Once-Daily form of tacrolimus spare liver transplant patients from side effects?